Fintech PR
XRP Healthcare & The Burnratty Investment Group on target for $100 Million ‘Super Fund’ to Transform African Healthcare Sector
LONDON, Oct. 5, 2023 /PRNewswire/ — Earlier this year, XRP Healthcare marked a pivotal moment in its journey by announcing a strategic partnership with The Burnratty Investment Group, laying the foundation for a dynamic expansion into the African healthcare sector. This ambitious collaboration, led by its subsidiary XRP Healthcare Africa, aims to acquire already profitable private healthcare businesses, including pharmacies, medical centres, and hospitals, commencing its operations in Uganda.
“Our strategic decision to invest in real-world healthcare businesses reflects our commitment to making a meaningful difference in people’s lives,” said Kain Roomes, CEO of Global XRP Healthcare. “Healthcare is an essential industry that demands innovation, and our investments will not only drive profitability but also contribute to enhancing healthcare services where they are needed most.”
The strategic partnership between XRP Healthcare and The Burnratty Investment Group signifies a monumental step towards advancing healthcare access and quality across the East African region.
“Our acquisition plan is a testament to our unwavering commitment to transforming healthcare in East Africa,” affirmed Mukisa Joshua William, the Principal and Founding Executive Director at The Burnratty Investment Group. “We recognize the potential of existing healthcare facilities and are dedicated to modernizing and upgrading them to meet the evolving healthcare needs of the region. The plan will not only result in the acquisition and refurbishment of existing healthcare facilities but also create opportunities for employment, stimulate local economies, and contribute to the overall growth and development of the African healthcare infrastructure.”
To bolster their strategic move into Africa’s burgeoning healthcare sector, XRP Healthcare has enlisted the expertise of FasterCapital, a distinguished investor incubator led by CEO Hesham Zreik. With a remarkable investment portfolio exceeding 100 startups, Hesham Zreik secured a coveted ranking of #39 among Forbes’ top 50 investors in 2018. FasterCapital, renowned for its outstanding track record, has facilitated funding for more than 428 startups, raising over $1.6 billion since its inception in 2010.
Hesham Zreik, CEO of FasterCapital said, “This vision is expansive, and we do not have a shortage of viable investors that are interested in investing, especially in a burgeoning industry such as the healthcare sector.”
Having successfully navigated various stages of due diligence and preparation, XRP Healthcare and The Burnratty Investment Group are now poised for the next critical phase of their journey. FasterCapital will play a pivotal role in introducing them to potential investors, facilitating interviews, and paving the way for their ambitious expansion plans.
XRP Healthcare and The Burnratty Investment Group have set fundraising targets. They seek to initially raise US $3,000,000, followed by a groundbreaking US $100,000,000 ‘Super Fund.’ This ‘Super Fund’ will drive the acquisition of 2,000 private healthcare establishments across Africa. This audacious endeavour aims to dominate and consolidate the multi-billion-dollar African healthcare sector within a span of 3 to 5 years and exit at a billion-dollar valuation.
XRP Healthcare and The Burnratty Investment Group, spearheading an ambitious healthcare venture in East Africa, proudly introduce their remarkable team, boasting a collective experience of over 250 years across the domains of Mergers and Acquisitions, Healthcare, and Business Development. This formidable team has a track record of creating over $20 billion in combined wealth, with board members serving as either direct or indirect participants.
Driven by a market overview that underscores the immense potential and urgent need for transformation. The African healthcare market, valued at a staggering $249 billion, presents a substantial opportunity for innovative healthcare providers as well as investors, to make a significant impact.
Despite the substantial market size, approximately 600 million Africans still lack access to quality healthcare services. This alarming statistic highlights the critical need for improved healthcare infrastructure and services, particularly in underserved regions. XRP Healthcare and The Burnratty Investment Group are committed to addressing this disparity and enhancing healthcare access and quality for millions of Africans.
Uganda, a country at the heart of this transformational journey, is home to approximately 4,000 private healthcare facilities. These facilities play a crucial role in the healthcare ecosystem, providing essential services to communities across the nation. XRP Healthcare and The Burnratty Investment Group’s strategic acquisition approach in Uganda will not only elevate the quality of healthcare but also contribute to the growth and development of the local healthcare sector.
With a target of acquiring 20 to 30 healthcare facilities per month, this strategic initiative aims to elevate healthcare access and quality by upgrading and modernizing existing establishments.
The core focus of this acquisition plan is to implement comprehensive improvements, including the introduction of telepharmacy services, facility refurbishment, and the integration of new and enhanced medical equipment and technology which will include NASA-designed ventilators.
With a population of 45.74 million*, Uganda stands out as one of the global leaders in traffic fatalities. Dr. Annet Alenyo Ngabirano, President Emeritus of the African Federation for Emergency Medicine (AFEM), recently shed light on Uganda’s healthcare challenges. From her perspective as a medical professional, she underscored how the COVID-19 pandemic has exposed the inadequacy of available medical equipment for prehospital emergency care. It’s particularly concerning given that the latest data reveals a mere 1.3 ICUs per million people in Uganda, with ICUs typically being the critical spaces housing ventilators for severe medical conditions.
By breathing new life into these healthcare facilities, XRP Healthcare and The Burnratty Investment Group seek to provide the African population with better access to high-quality healthcare.
About XRP Healthcare: XRP Healthcare is the first Pharma and Healthcare platform to be built on the XRP Ledger. XRP Healthcare aims to profoundly impact healthcare infrastructure, services, and innovation.
The Burnratty Investment Group: The Burnratty Investment Group is a renowned investment firm that aims to dominate and consolidate the highly fragmented billion-dollar African healthcare sector through the merger and acquisition of small and medium-sized healthcare businesses.
FasterCapital: FasterCapital is an investor incubator specializing in connecting startups with compatible investors. Under the leadership of CEO Hesham Zreik, FasterCapital has a remarkable track record of assisting startups in securing funding and achieving their growth objectives. Established in 2010, the organization has played a pivotal role in securing funding for more than 428 startups, raising over $1.6 billion to date.
Photo – https://mma.prnewswire.com/media/2239311/XRP_Healthcare.jpg
Logo – https://mma.prnewswire.com/media/1983109/XRP_Healthcare_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/xrp-healthcare–the-burnratty-investment-group-on-target-for-100-million-super-fund-to-transform-african-healthcare-sector-301947742.html
STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.
The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.
To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.
The webcast can be followed live here and a recording will be available afterwards.
Information on EQT AB’s financial reporting
The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.
The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.
Contact
Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]
Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/eqt/r/invitation-to-presentation-of-eqt-ab-s-q1-announcement-2024,c3956826
The following files are available for download:
|
Invitation to presentation of EQT AB’s Q1 Announcement 2024 |
|
|
EQT AB Group |
View original content:https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-eqt-abs-q1-announcement-2024-302109147.html
- Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
- Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
- Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
- Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
- PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
- Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
- 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
- CEO reaffirms Kia’s commitment to ESG management
SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.
Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.
During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.
The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.
“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”
Photo – https://mma.prnewswire.com/media/2380039/Photo_1__2024_CEO_Investor_Day.jpg
PDF – https://mma.prnewswire.com/media/2380040/Press_Release__2024_Kia_CEO_Investor_Day_240405.pdf
View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/kia-presents-roadmap-to-lead-global-electrification-era-through-evs-hevs-and-pbvs-302109142.html
VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.
Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.
About BioVaxys Technology Corp.
BioVaxys Technology Corp. (www.biovaxys.com), a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit www.biovaxys.com and connect with us on X and LinkedIn.
ON BEHALF OF THE BOARD
Signed “James Passin“
James Passin, Chief Executive Officer
Phone: +1 646 452 7054
Logo – https://mma.prnewswire.com/media/1430981/BIOVAXYS_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/biovaxys-technology-corp-provides-bi-weekly-mcto-status-update-302108920.html
-
Latest News4 days ago
Clayfin Technologies and Jana Small Finance Bank Honored with Prestigious IBSi Digital Banking Award 2024
-
Latest News4 days ago
HANDSHAKE SPEAKEASY IN MEXICO CITY NAMED AS THE BEST BAR IN NORTH AMERICA AS RANKING OF NORTH AMERICA’S 50 BEST BARS IS REVEALED AT THIRD ANNUAL AWARDS CEREMONY
-
Latest News3 days ago
Trakx launches a new product: Trakx USDc Earn CTI powered by OpenTrade
-
Latest News5 days ago
Nium Expands Regional Footprint in Asia; Signs Partnership MOU with Indonesian Payments Infrastructure Leader, Artajasa
-
Latest News6 days ago
Colombia to showcase sustainable investment opportunities at the Investment Roadshow in London
-
Latest News4 days ago
SDAX Unveils World’s First Securitised Gold Tokens for Digital Exchange Users
-
Latest News5 days ago
Fortis Digital Solutions secures $20 million Series A funding to expand its presence in the MENA region
-
Latest News4 days ago
BINGHATTI LAUNCHES ITS DEBUT PROJECT ADJACENT TO DUBAI HILLS